Inicio | CNIO Friends | With little help from our friends

It is thanks to all our “Friends” that these young researchers have been contributing to our understanding of common childhood tumors. Nor should we omit mention of progress being made against pancreatic cancer, one of the most aggressive forms of the disease. At the same time, they are developing mechanisms that will allow targeted medication to be “aimed” at its target with greater accuracy. Their work has also encouraged them to explore new strategies for halting the proliferation of tumoral cells.


“CNIO Friends” Post Doc Researchers

Carolina Maestre
Carolina Maestre
One of the beneficiaries is Carolina Mestre, who is looking closely at what could prove to be a new target for pharmacological-based cancer treatments. “We have identified a molecule involved in the survival of tumoral cells when they divide. Our working hypothesis is that if we can manage to inhibit the action of those molecules, it should keep the tumor from spreading.”
Sebastián Thompson
Sebastián Thompson
Is examining the process by which nanoparticles can be used to transport medication to a specific location in the body, on account of their enhanced ability to reach the compromised cells. “We are searching for the best way to make certain that the greatest possible number of nanoparticles actually make it all the way to the tumor location,” he explains.
Miguel Jiménez Alcázar
Miguel Jiménez Alcázar
(CNIO Friends/Play Therapy Foundation) has undertaken a study focusing on gliomas, cerebral tumors common in children and adolescents. His goal is to see that “the results are transferred to the clinical sphere, where they can contribute to increasing patients’ survival rates and improving the quality of life.”
Irene Felipe
Irene Felipe
(CNIO Friends/Play Therapy Foundation) has made a special study of the neuroblastoma, one of the tumors most frequently seen in children. “We hope that in the near future, breakthroughs on the molecular level will lead to new clinical applications” as will the translational aspects of our work, such as the identification of therapeutic strategies and development of biomarkers.

Up